← SynDRA
PEMIGATINIB
SynDRA canonical compound SYN0039668 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx |
|---|
| Primary target(s) | FGFR1 | FGFR2 | FGFR3 |
|---|
| Mechanism of action | fgfr inhibitor |
|---|
| Indication | colorectal cancer |
|---|
| Disease area | oncology |
|---|
All known targets
Mechanisms of action (all sources)
- FGFR2 INHIBITOR
- Fibroblast growth factor receptor 2 inhibitor
- FGFR3 INHIBITOR
- Fibroblast growth factor receptor 3 inhibitor
- FGFR1 INHIBITOR
- Fibroblast growth factor receptor 1 inhibitor
- fgfr inhibitor
Drug classes
- Kinase Inhibitors
- Kinase Inhibitor
- P-Glycoprotein Inhibitors
- Organic Cation Transporter 2 Inhibitors
- Multidrug and Toxin Extrusion Transporter 1 Inhibitors
ATC classes
- L01E · PROTEIN KINASE INHIBITORS
Cross-references
Synonyms
- pemazyre
- INCB054828
- Fgfr inhibitor incb054828
- Incb-054828
- Pemazyre
- Unii-Y6BX7BL23K
- Y6BX7BL23K
- GTPL9767
- SCHEMBL15556271
- HCDMJFOHIXMBOV-UHFFFAOYSA-N
- example 126 [WO2014007951]
- 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-4,7-dihydropyrrolo[4,5]pyrido[1,2-d]pyrimidin-2-one
- 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-1,3,4,7-tetrahydro-2H-pyrrolo[3',2':5,6]pyrido[4,3-d]pyrimidin-2-one
- INCB54828
- INCB-054828
- Fgfr inhibitor INCB054828
- pemigatinibum
- RefChem:58318
- DTXCID401513523
- Pemigatinib [INN]
- Pemigatinib [USAN]
- INCB 54828
- Pemigatinib?
- Pemazyre (TN)
- MFCD31706227
- Pemigatinib (Standard)
- PEMIGATINIB [MI]
- PEMIGATINIB [JAN]
- Pemigatinib [USAN:INN]
- UNII-Y6BX7BL23K
- PEMIGATINIB [WHO-DD]
- Pemigatinib (JAN/USAN/INN)
- Pemigatinib (INCB054828)
- SCHEMBL29357782
- PEMIGATINIB [ORANGE BOOK]
- C24H27F2N5O4
- BDBM301310
- GLXC-21245
Reported adverse events
- Alopecia
- Arthralgia
- Constipation
- Dry eye
- Dry mouth
- Dry skin
- Dysgeusia
- Fatigue
- Nausea
- Stomatitis
- Trichiasis
- Vision blurred
Look up PEMIGATINIB in the interactive SynDRA portal →